Compare Apple Inc (AAPL) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apple Inc vs Sana Biotechnology Inc — how do they compare? Apple Inc trades at $314.58 (market cap $4.56T), while Sana Biotechnology Inc trades at $3.98 (market cap $1.15B). The key difference: Apple Inc is far larger — about 3965.2× Sana Biotechnology Inc's market cap, and Apple Inc pays a 0.35% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| AAPL | SANA | |
|---|---|---|
Market Cap | $4.56T | $1.15B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $5.92 |
52-Week Low | $202.38 | $2.68 |
Enterprise Value | $4.58T | $1.12B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apple (AAPL) trades at $314.13, up 0.47% today, with a bullish technical outlook and strong institutional support. The stock shows robust fundamentals with 2025 revenue of $416.16B and net income of $112.01B, beating earnings estimates in recent quarters. Analyst consensus is bullish with a $329.62 price target, though valuation ratios like P/E of 37.61 and P/B of 42.85 suggest premium pricing. Recent news highlights AI potential via a partnership with Alphabet's Gemini and ongoing retail adjustments.
Outlook remains positive driven by earnings growth and AI integration, but risks include high valuation sensitivity, competitive pressures, and regulatory scrutiny. The stock offers stability with consistent cash flow and dividend payments, yet investors should weigh premium multiples against growth sustainability in a challenging macro environment.
SANA Biotechnology trades at $3.97, down 1.0% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative ROE and ROA, while analyst consensus is strongly bullish with 82% buy ratings. Recent news highlights clinical data presentations and a $69 million share sale via an ATM facility in May 2026.
Outlook remains speculative with high investor optimism driven by clinical progress, but significant financial losses and cash burn pose risks. Upside depends on successful drug development, while downside risks include funding needs and trial setbacks. The stock offers high-risk, high-reward potential for biotech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
